ODIN Biotech Partners Company
%20.jpg)
ODIN Biotech Partners, LLC is a development-stage biotechnology company focused on developing novel peptide therapeutics for diseases of the retina. ODIN’s lead product, C16Y, is currently in preclinical development for the treatment of wet age-related macular degeneration (AMD). ODIN expects to begin clinical studies of C16Y in early 2016.
Founded Date:
1-1
Last Funding Type:
Seed
Headquarters:
Dallas, Texas, United States
Investors Number:
2
Technology:
Geroscience
Employee Number:
1-10
Industry:
Biotechnology, Medical, Therapeutics
Funding Status:
Seed
Investor Type:
For Profit
Total Funding:
$250K